THE CLINICAL PATHWAY AND COST OF TREATMENT ON METHADONE MAINTENANCE IN RUMAH SAKIT KETERGANTUNGAN OBAT JAKARTA (DRUG DEPENDENCE HOSPITAL JAKARTA)
|
|
- Ophelia Warner
- 7 years ago
- Views:
Transcription
1 THE CLINICAL PATHWAY AND COST OF TREATMENT ON METHADONE MAINTENANCE IN RUMAH SAKIT KETERGANTUNGAN OBAT JAKARTA (DRUG DEPENDENCE HOSPITAL JAKARTA) Ronnie Rivany Lecturer, University of Indonesia Abstract The drug abuse results in increasing HIV/AIDS prevalence among drug users using injection. Methadone Maintenance Treatment Program (MMTP) is an alternative way for the treatment that at present has not yet equipped with 1) clinical pathway and 2) cost of treatment as standard average cost of health care services. The purpose of this study was to design and applied clinical pathway and cost of treatment of MMTP along with its casemix in Drug Dependence Hospital Jakarta (DDHJ). The method used INA-DRG (Rivany, 2008) which is based on evidence from medical record and focus group discussion between medical and non medical staff, related professional organization and hospital management. Based on numbers and types of treatment utilization in clinical pathway, cost of treatment was done using activity based costing with simple distribution method. The result showed that the length of stay for MMTP was 338 days, with casemix that consist of TBC, Hepatitis, HIV/AIDS and its combination. Treatment cost for MMTP was IDR with the casemix for complicating disease ranging from IDR to IDR and IDR to IDR for casemix with combination of complicating and incurring diseases. Key Words : INA-DRG s, Diagnosis Related Group, Clinical Pathway & Cost Of Treatment *) Health Policy and Administration Department, Faculty of Public Health, University of Indonesia, 1 st floor - F Building, UI Campuss, Depok 16424, Indonesia ( ronnie rivany@yahoo.com) Introduction The effect of the drug abuse is very complex covering the problems in legal, social, economic and health. Based on the BNN (National Narcotic Organization) and Puslikes UI (The Center of Health Research University of Indonesia) 2005, it was revealed that the number of drug abuse prevalence in Indonesia was 1,5% - 1,9% (3.5 4,5 millions) of the Indonesian population. Drug abuse in High School and University students in 2003 was 3.9%. The effect of social economy caused by the misuse and the illegal circulation of drugs in Indonesia was Rp trillions. The cost consisted of the social cost of Rp trillions and the economical cost of Rp trillions, and around Rp trillions as the cost of drugs purchase (1). It was assumed that in 2005 around 38.6 millions of people suffered from HIV in the world. At least around 4.1 millions of people suffered new infection and around 2.8 millions died because of AIDS. In November 2006 Department of Health showed the fact that the drug users using injections in Indonesia who were infected by HIV was very high that was 46%. Therefore, the program for the control of the bad effects from the transfer by drug injecting users (harm reduction) was badly needed. Based on the Decision by the Ministry of Health of the Republic of Indonesia No. 464/MENKES/SK/VII/2006 in regards to the Hospital Allocation and the Trial Satelit on Methadone Therapy and the Guideline on Methadone Maintenance Therapy, it was decided that Drug Dependence Hospital Jakarta (DDHJ, Rumah Sakit Ketergantungan Obat Jakarta) as the Trial Hospital for the service of Methadone Maintenance Therapy. Methadone Maintenance Therapy Program is the substitute therapy to reduce the bad effects of HIV/AIDS transfer trough needle injections (2). Methadone Maintenance Therapy Program consists of three (3) steps covering induction, 42
2 stabilization and maintenance phases. In the Induction phase the severity on the dependency and the consumption of other sedative drugs must be watched. The maximum dosage that can be given in the Induction phase is 30 mg/d and the patient s condition must be monitored for the first 4 hours after it is given to see the any rejection or intoxication signs. The dosage can be increased every 4 days with the maximum dosage of 40 mg (2.3) in the first week. In United States, the programs for Methadone Maintenance Therapy must have the FDA agreement and license and also the agreement from the related country. The aim of this program is to stop the drug dependence completely. To join this program, it needs a proof that the patient has drug dependence of morphine type and has suffered at least 2 years. Methadone is dl-4.4 difenyl-6-dimetylamino-3-heptanon which is available in 2 forms. L-methadone is analgesic with the strength 8-50 times more than d-methadone. The analgesic effect in 7,5-10 mg methadone is equal to 10mg morphine. The side effect occurred more in oral administration compared with parenteral administration. The main danger in using suitable dosage of methadone is the decrease of pulmonal ventilation. The choice of the opiat as the analgesic depends on the patients acceptance, analgesic effectivity, pharmacokinetic, pharmacodynamic and the side effect profile. Methadone is classified as opioid matter which pharmacologically used to relieve the pain where the methadone outcome reaches minutes with its half time hours. Methadone is synthetically manufactured and can be administered intramuscularly and per orally (4.5). ICD X-WHO (6) and Australian Refined DRG put the disease into several Major Diagnostic Category (MDC) which is divided into 3 categories which are surgery, other, and medical, that further can be classified into several Diagnosis Related Group s (7). DRG s is a way to identify patients who have needs on the same sources in the hospital and it is further grouped into a group that is easily managed technically and related also to the casemix incurred ( ). Specifically for this drug/opioid (Opioid Drug Dependence Disorders), complied with AR- DRG Opioid Dependence included in MDC 20 with DRG V.63A and V.63B classification. Opioid dependence does not cause the patient to be hospitalized, but because of the incurring and/or complicating diseases such as TBC- Hepatitis and HIV/AIDS, the patient must be hospitalized. Clinical pathway is a concept of complete services that covered every step given to the patient based on the medical services, the standards of nurse care and the standard of health team services. The service based on the proof with a result that can be measured and in a certain period during hospitalization. Clinical pathway is an audit tool for the management and the clinical condition, starting from the patient s registration and ending when the patient is recovered and discharged (8,9,10,11). Clinical pathway combine the plan for health service and nurse care with other therapies such as nutrients, physiotherapy, and mental state. Clinical pathway is not a standard for the service or the substitute for clinical assessment or doctor s orders, but as an integrated document to simplify the patient s care process and to make the clinical and financial services effective by combining the team and clinical approach. The problem in Indonesia is that the control of HIV/AIDS spread on drug users using injections is agreed to be treated with Methadone Maintenance Therapy. However until today there is no clinical pathway that can be used as a reference or quality control in servicing. Besides that, it is the fact that there is no calculation on the cost of treatment from Methadone Maintenance in the Technical Application Unit (TAU/UPT) in Health Ministry environment. Survey based on INA- DRG (12) aimed to obtain clinical pathway and the calculation of cost of treatment on Methadone Maintenance in UPT/TAU Hospital under Indonesian Ministry of Health. Material and Method The population in this survey were all patients with main diagnose when discharged, whereas the samples for all patients with the Opioid Dependence Disorders (ODD) with main diagnose when discharged and Methadone Maintenance chosen as medical treatment within the last year in the Hospital. The criteria include : 1) Discharged patients who already recovered and considered had completed their medical treatment with main diagnose/entered and 43
3 discharged at the same time, and 2) The patients had complete medical record status. Secondary data taken from the inpatient medical record within the last 1 year, whereas primary data was on the interview, observation and Focus Group Discussion (FGD) with the Professional Association / Perhimpunan Dokter Spesialis Kesehatan Jiwa (PDSKJ/The Association for the Mental Health Specialist) with the doctor, nurse and related hospital management whereas the activity results data was taken from the Hospital s latest year profile. The cost on medical treatment was calculated based on clinical pathway by using activity based costing method for its direct cost and simple distribution method for its indirect cost. The cost level in this survey was the degree of the cost which happened because of the degree of severity (7) which showed the comparison between the Methadone Maintenance Therapy in Opioid drug dependent patients group and the group of opioid drug dependent patients with the complicating and incurring diseases (casemix). Result Patient s characteristic Around 92.05% of patient who underwent Methadone Maintenance Therapy were males. Two major groups were between the age more than 30 y.o (>30 y.o) and a group with the age y.o (25-30 y.o). Around 67.04% of these patients were already underwent Methadone Maintenance Therapy more than 6 months and around 32.95% just underwent the therapy less than 6 months (Table 1). Table 1. Gender characteristic, age, and the therapy duration on the Methadone Maintenance Therapy patient at RSKO Jakarta in 2009 (n=88) Characteristic Category Total number Percentage Sex Men Women Age < 25 y.o y.o > 30 y.o Therapy duration <= 6 month > 6 month Total The degree of severity in the group of patients with drug/opioid dependence showed a mix case which was called casemix. From the survey result, a number types of diseases suffered by the methadone maintenance therapy patients in this casemix such as TBC, Hepatitis and HIV/AIDS. Around 59 (67.05%) methadone maintenance therapy patients did not have complicating and incurring diseases or only suffered opioid dependence problems and further called Pure Methadone Maintenance patients. Casemix which showed the patient distribution frequency with HIV/AIDS was 19.32%, patient with TBC was 1.14% and patient with Hepatitis was 2.27%. Patients who suffered from the complicating and incurring diseases between TBC and HIV/AIDS was 7.95% and patient with complicating and incurring diseases between Hepatitis and HIV/AIDS was 2.27% (Table 2). Table 2. Type of complicating and incurring in Methadone Maintenance Therapy patients at RSKO Jakarta in Patient Status Frequency Percentage Opioid addicted (ODD) ODD + TBC ODD + Hepatitis
4 ODD + HIV/Aids ODD + TBC + HIV/Aids ODD + Hepatitis + HIV/Aids Total Note : Opioid drug dependence = opioid dependence disorder Clinical Pathway Based on the recapitulation on the treatment and utilization obtained from the patients medical record with the opioid dependence, the clinical pathway draft was done by calculating the average score on the treatment, and then mean score or median was calculated based on the distribution. The average score obtained will be used as basic material to perform FGD. Based on the FGD result which was performed by the Perhimpunan Dokter Spesialis Kesehatan Jiwa (PDSKJ, The Association of Mental Health Specialists), dokter Poli Terapi Rumatan Metadon (Methadone Maintenance Therapy polyclinic doctors),doctor-other related non medical and hospital management staffs, the clinical pathway for the opioid dependence patient group and opioid dependence patients group and its casemix was obtained. The finalization on the total number and the type of the utilization treatment was based on the agreed clinical pathway (Table 3). Table 3. The total number and treatment type on the clinical pathway of pure Methadone Maintenance Therapy with complicating and incurring patients, at RSKO in NO ACTIVITY UTILIZATION I REGISTRATION 1. Outpatient policlinic Methadone policlinic II DIAGNOSE (Napza policlinic) 1. Psychosocial data Medical chek up Starting registrating data The drug user historical data and his/her treatment Major diagnostic application Commitment III THERAPY 1. Induction phase Stabilization phase Maintenance phase Counselling Group Supporting examination 1. Routine test a. Routine blood test b. SGPT c. SGOT d. VCT e. Napza Urinalysis Additional test Test Anti HIV CD BTA 2 2 Thorax photo 3 3 SGOT
5 SGPT 3 3 HbsAg 1 1 HbeAg 1 1 USG 1 1 HBV-DNA Psychology Drug administration Main drug (Methadone) 20 mg mg mg Additional drug standard TBC 1 1 Hepatitis 1 1 ARV Note : 1 = The opioid drug dependence patients group (ODD), 2 = ODD + TBC, 3 = ODD + Hepatitis, 4 = ODD + HIV/AIDS, 5 = ODD + TBC + HIV/AIDS, 6 = ODD + Hepatitis + HIV/AIDS The clinical pathway which was agreed in the FGD result e.g. : 1) Methadone Maintenance Therapy is for outpatients therapy; 2)The opioid drug dependence does not cause the patient to be hospitalized but because of the casemix with complicating and incurring diseases the patients must be hospitalized; 3)The presence of complicating and incurring diseases as a casemix are TBC, Hepatitis and HIV/AIDS with different kinds of levels. Specifically, the steps in the clinical pathway of Methadone Maintenance are : 1) Registration, to show the number of visits for the patients group that actually differ/same in the degree of severity with opioid drug dependence patients group, and the patients group with opioid drug dependence with casemix, 2) Diagnostic application performed in Napza polyclinic where the utilization on the medical check up will also vary according to their degree of severity along with their commitment and consistency for their treatment, 3) The therapy phases include : (a) Induction phase for 4 (four) days, (b) Stabilization phase for 11 (eleven) days and (c) Maintenance phase including group counseling of minimal 10 times within 10 months; (d) The supporting examination for Methadone Maintenance including routine blood test, SGPT, SGOT, Voluntary Counseling Test (VCT), Urinalysis. For the additional examination will be given according to their casemix, such as anti HIV test given once to all the patients group, CD4 given once to the patients group with HIV casemix and twice (2x) for BTA examinations, 3x (three times) for thorax photos, 3x (three times) for SGOT- SGPT examinations for the patient group with TBC casemix. For the patients group with Hepatitis casemix the tests that must be carried out minimum of 1x (once) : HBsAg, HBeAg, USG and HBV DNA; (e) Psychological examination for each group of patients ; (f) The main drug (Methadone) administration starting with the dosage 20 mg for 4 times, dosage 100mg for 11 (eleven) times and dosage 60 mg within 323 days. For the additional drug administration which is symptomatic should be given according to the needs for additional drug such as for TBC, Hepatitis and Anti Retro Viral which is suitable to each patients group. Specifically for the number and type of utilization for the medical service given, FGD agreed that there is linear correlation from each clinical pathway phases, whereby with the present of casemix that cause the degree of severity, starting from number 1 that is opioid drug dependence patients groups, up to number 6 for the opioid drug dependence group with TBC, HIV/AIDS and Hepatitis casemix. Cost Of Treatment The amount of cost of treatment based on the clinical pathway can be calculated by multiplying the unit cost with the utilization in each clinical pathway phases. The cost of treatment and cost level between methadone maintenance patients with casemix is shown in table 4. 46
6 Table 4. Cost of treatment and cost level on methadone maintenance patient and their casemix Complicating and incurring diseases COT CL Opioid Addiction (ODD) ODD + TBC ODD + Hepatitis ODD + HIV/Aids ODD + TBC + HIV/Aids ODD + Hepatitis + HIV/Aids Note : COT = Cost Of Treatment, CL = Cost Level By assuming than the amount the cost of treatment in ODD group is =1, the methadone maintenance therapy patients group with the complicating Hepatitis (CL = 3.07) and its complication (CL = 3.24) a very high cost of treatment is needed than with other complicating diseases. Disscussion Patients who underwent methadone therapy at RSKO (DDHJ) were mostly males that is 92%. The surveys which was performed by BNN and Puslitkes-UI in 2005, showed that the majority (79%) of drug users using injections were males. The high prevalence in male drug users also triggered the high prevalence of HIV/AIDS(1). Based on the AIDS Control Commission (KPA) up to June 2007 the data obtained was that the ratio in living person with HIV (ODA) in males was 4 x more than in female. From the survey s result it was obvious that males have higher risk to contract HIV from the injection more than females. Looking at the above statement, the program for using condom for the drugs addicts suffering from HIV/AIDS and the program for free needle offer, should be emphasized more to males drug addict than to females. This will reduce the HIV/AIDS transfered both by sexual contact or by sharing needle for injection. The age average of the methadone maintenance patients cases is 30,2 years, and the minimum age is 21 y.o and maximum age is 49 y.o. The period from age 21 y.o up to 49 y.o is the productive age period, where they are potential workers. The addiction to injecting drugs has caused them unable to work optimally due to the heroin effect causing the addiction. The clinical pathway for the methadone maintenance therapy obtained, based on the recapitulation of the average score and the type of medical treatment in patients medical record (12). That average score was used as basic discussion materials among the specialist to reach an agreement in clinical pathway where these discussion result as the basic for cost of treatments calculation. Specifically for the decision on methadone maintenance it was agreed that this therapy is for the outpatients and not for the inpatients where it was similar to the Australian Refined- Diagnosis Related Groups (AR-DRG) that include the disease group with opioid drug dependence patients into Major Diagnostic Categories no.20 (MDC 20) group with the Diagnosis Related Group no. V63A and V63B which was the disease with opioid dependence (7). The cost of treatments were calculated by multiplying clinical pathway in each phase with the unit cost of each phase, the sum result was the whole cost of treatment based on the clinical pathway (13,14). The utilization difference between one disease and other complicating diseases is caused by the fact that the patients must have laboratory tests to confirm on the diagnosis of the diseases they suffer and to see their physical condition in general because of the therapy combination effect. Besides that the patient must be given the medication which was for the disease she/he was suffering. The utility increase in health facility caused the increase in cost of treatments (17). In this case the cost of treatment was the expense from the hospital aspect which was needed for the pure methadone maintenance therapy for 338 days which is Rp. 47
7 For the methadone maintenance therapy with complicating TBC was Rp in methadone with complicating hepatitis which was Rp with the highest cost component that was the cost for extra medicine. The cost of treatment for the methadone maintenance therapy patients with complicating HIV/AIDS was Rp whereas the methadone maintenance therapy with complicating and incurring TBC and HIV/AIDS was Rp with the highest cost component was the maintenance phase cost. Finally, the amount of the cost for the methadone maintenance patient with complicating Hepatitis disease and HIV/AIDS which was Rp , with the highest cost component was the cost for the additional medicines. The cost for the treatment for chronic and long life diseases was adjusted to the length of the methadone maintenance therapy that was 338 days. Based on the cost level between one and other diseases, the cost of treatments for the methadone maintenance therapy with the complicating diseases TBC and HIV/AIDS or both only causing the cost increase 1.6 and 1.25 with 1.29 of the cost for Pure Methadone Therapy. This was caused by the additional cost of medicine and counseling which was not too high. It differed from the cost of treatment with the complicating Hepatitis or complication of Hepatitis, the medical cost became 3.07 and 3.24 from the medical cost of pure methadone maintenance therapy. The use of interferon as the therapy for hepatitis must be given for one year so that the patient could be completely recovered from hepatitis. Conclusion Based on the survey results of the clinical pathway and cost of treatment in methadone maintenance patient at RSKO Jakarta (DDHJ), it can be concluded that the casemix or complicating and incurring diseases are known as TBC, Hepatitis and HIV/AIDS and the combination of both. From the FGD result it is also agreed that methadone maintenance therapy is inpatients therapy and needs therapy time 338 days with the cost of treatment in the ODD group which is Rp with CL = 1, the highest cost of treatment of Rp resulted because the patient is given interferon. Suggestion From the aspect in policy it needs to be suggested to review Kepmenkes NO 464/Menkes/SK/VII/2006 about the length of therapy in methadone maintenance patient because of the survey result showed that the length of maintenance therapy is in fact more than 6 month and up to 338 days or 10 (ten) months. From the operational technical aspect in Rumah Sakit Ketergantungan Obat Jakarta (RSKO/DDHJ), the activity and the efficiency must be noticed by looking into the output and the cost structure related to the clinical pathway phases and the methadone maintenance cost of treatment, where as a whole further program in maintenance therapy is needed. From the INA-DRG development aspect, the adjustment from MDC.20 with the Diagnosis Related Group no V63A and V63B must be thought of, because it is found that there are casemix as with TBC, Hepatitis and HIV/AIDS and the combination of both which can cause a degree of severity. References 1. Puslitkes UI, Studi Biaya Sosial dan Ekonomi Penyalahgunaan Narkoba, Jakarta Departemen Kesehatan Republik Indonesia, Keputusan Menteri Kesehatan Republik Indonesia nomor 49/MENKES/SK/VII/2006, tentang penetapan rumah sakit dan Satelit uji coba pelayanan terapi rumatan metadon serta pedoman program terapi rumatan metadon, Pedoman Pelaksanaan Program Terapi Rumatan Metadon, Departemen Kesehatan RI, Kusnady, Andy A, 2007, Rumatan Metadon di Indonesia, 5. net/?=content/terapi-rumatanmetadon-di-indonesia. 6. World Health Organization, Regional Office for South East Asia, Operational guidelines for the management of opioid dependence in the South East Asia Region, World Health Organization, International Statistical of Diseases and Related Health problems -10 th Revision, 2 nd Ed, Geneva, Australian Defined Diagnosis Related Group, Definition Manual, Australian 48
8 Government Department of Health dan Ageing, Commonwealth of Australia, Rivany, Ronnie. Hubungan Clinical pathway dengan DRG s Casemix, INA-DRG s, FKMUI, Departemen Kesehatan Republik Indonesia, Clincal pathway di Rumah Sakit Direktorat Bina Pelayanan Medik Depkes RI, Europian Pathway Association, Clinical/Care Pathway, Amrizal, M.N, Introduction of Clinical pathway-casemix, Rivany Ronnie. Reg Hak Kekayaan Intelektual-Departemen Hukum dan HAM RI untuk INA-DRG s Nomor C , Jakarta Feyner, R, et all, Cost Profit- Accounting based on Clinical pathway for CABG: A Practical Tool for DRG-Implemmentation, Rosch, J, et all, Cost Unit Accounting Based on Clinical pathway, Harmidy, F.F, Cost Index dari biaya pengobatan Penyakit Diare Anak dan Tindakan Sectio Caesaria di RSUD DKI Jaya, Tesis, Fakultas Kesehatan Masyarakat, Universitas Indonesia. 17. Julian, 2008, Biaya pengobatan Cholelitiasis dengan Laparoscopic Cholecystectomy berdasarakan DRG s, Tesis, Fakultas Kesehatan Masyarakat, Universitas Indonesia. 18. Dinas Kesehatan Provinsi DKI Jakarta, Analisis Biaya Berbasis Paket Diagnosa Related Groups (DRG s),
AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS
AN OVERVIEW OF PROGRAMS FOR PEOPLE WHO INJECT DRUGS Helgar Musyoki MARPs and Vulnerable Groups Program National AIDs/STI Control Programme November 2012 Background Injection of heroin in Kenya reportedly
More informationBuprenorphine/Naloxone Maintenance Treatment for Opioid Dependence
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
More informationObjectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.
Addiction Psychiatry Program Site Specific Goals and Objectives Addiction Psychiatry (ADTU) Goal: By the end of the rotation fellow will acquire the knowledge, skills and attitudes required to recognize
More informationModule 6 Alcoholism, Drug Abuse and Corruption
Module 6 Alcoholism, Drug Abuse and Corruption Lecture 36 Drug Abuse: Concept, Extent and Nature Concept Any substance (usually chemical) which influences our bodies or emotions when consumed may be called
More informationPolicy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
More informationAproved by order No 702 as of 22 12 1997 by the Ministry of Health Care
Translation form Lithuanian THE MINISTRY OF HEALTH ORDER OF THE REPUBLIC OF LITHUANIA 22 12 1997 No 702 Vilnius Conformation of the application procedure of Substitution therapy to opioid addicts In September
More informationNaltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently Asked Questions What is Naltrexone? Naltrexone is a prescription drug that effectively blocks the effects of heroin, alcohol,
More informationA Nurse Practitioner led opiate substitution prescribing clinic The
A Nurse Practitioner led opiate substitution prescribing clinic The X First Forty Fifty Four Stephen Ling Nurse Practitioner Drug and Alcohol, Hunter New England Local Health District Conjoint Teacher,
More informationDevelopment of the guidelines on the pharmacotherapy of addiction case study Croatia
Development of the guidelines on the pharmacotherapy of addiction case study Croatia Croatia Marina Kuzman Dragica Katalinic Croatian National Institute of Public Health Cyprus, 2009. Drug use and drug
More informationLike cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
More informationNon medical use of prescription medicines existing WHO advice
Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations
More informationTable of Contents. I. Introduction... 2. II. Summary... 3. A. Total Drug Intoxication Deaths... 5. B. Opioid-Related Deaths... 9
Table of Contents I. Introduction... 2 II. Summary... 3 III. Charts A. Total Drug Intoxication Deaths... 5 B. Opioid-Related Deaths... 9 C. Heroin-Related Deaths... 11 D. Prescription Opioid-Related Deaths...
More informationPractice Protocol. Buprenorphine Guidance Protocol
Practice Protocol Buprenorphine Guidance Protocol Developed by the Arizona Department of Health Services Division of Behavioral Health Services Effective Date: 02/23/11 Title Buprenorphine Guidance Protocol
More informationPrescriber Behavior, Pain Treatment and Addiction Treatment
Prescriber Behavior, Pain Treatment and Addiction Treatment Mary Fleming, M.S. Director, Office of Policy, Planning, and Innovation Substance Abuse and Mental Health Services Administration NGA Policy
More informationADVISORY OPINION THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF CHRONIC PAIN
Janice K. Brewer Governor Arizona State Board of Nursing 4747 North 7 th Street, Suite 200 Phoenix, AZ 85014-3655 Phone (602) 889-5150 Fax - (602) 889-5155 E-Mail: arizona@azbn.gov Home Page: http://www.azbn.gov
More informationOutpatient/Ambulatory Health Services
Outpatient/Ambulatory Health Services Service Definition Outpatient/ambulatory medical care includes the provision of professional diagnostic and therapeutic services rendered by a physician, physician
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationDrug Testing to Support Pain Management
NATIONAL REFERENCE LABORATORY Drug Testing to Support Pain Management 500 Chipeta Way, Salt Lake City, UT 84108 (800) 522-2787 (801) 583-2787 www.aruplab.com www.arupconsult.com ARUP is an enterprise of
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationKENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
More informationCollaborative Care for Pregnant Women with Substance Use Disorders
Collaborative Care for Pregnant Women with Substance Use Disorders Alane O Connor DNP Maine Dartmouth Family Medicine Residency MaineGeneral Medical Center Dartmouth Medical School Vanderbilt University
More informationFrequently asked questions
Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction Frequently asked questions What is Naltrexone? Naltrexone is a prescription drug that completely blocks the effects of all opioid drugs
More informationFRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents
More informationCocaine. Like heroin, cocaine is a drug that is illegal in some areas of the world. Cocaine is a commonly abused drug.
Cocaine Introduction Cocaine is a powerful drug that stimulates the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants
More informationImpact of Systematic Review on Health Services: The US Experience
Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol
More informationMEDICAL POLICY Treatment of Opioid Dependence
POLICY........ PG-0313 EFFECTIVE......11/11/14 LAST REVIEW... 07/14/15 MEDICAL POLICY Treatment of Opioid Dependence GUIDELINES This policy does not certify benefits or authorization of benefits, which
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationPresentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,
More informationROADMAP OF STANDARD MEDICAL SERVICES IN PRISONS AND DETENTION FACILITIES
ROADMAP OF STANDARD MEDICAL SERVICES IN PRISONS AND DETENTION FACILITIES The present roadmap is based on the Standards of Medical Services and Additional Standards of Medical Services for the Persons with
More informationmethadonefact.qxd 8/11/01 2:05 PM Page 1 INFORMATION Advantages of methadone treatment DEPRESSANT Methadone maintenance Pregnancy METHADONE
methadonefact.qxd 8/11/01 2:05 PM Page 1 INFORMATION Advantages of methadone treatment 10 DEPRESSANT Methadone maintenance Pregnancy METHADONE methadonefact.qxd 8/11/01 2:05 PM Page 2 WHAT IS METHADONE
More informationOutline. Drug and Alcohol Counseling 1 Module 1 Basics of Abuse & Addiction
Outline Drug and Alcohol Counseling 1 Module 1 Basics of Abuse & Addiction About Substance Abuse The Cost of Chemical Abuse/Addiction Society's Response The Continuum of Chemical Use Definitions of Terms
More informationTREATMENT MODALITIES. May, 2013
TREATMENT MODALITIES May, 2013 Treatment Modalities New York State Office of Alcoholism and Substance Abuse Services (NYS OASAS) regulates the addiction treatment modalities offered in New York State.
More informationEver wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier?
Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier? Good News: Medical treatments called opioid (oh-pee-oyd) maintenance can help you! Injecting heroin puts you
More informationResources for the Prevention and Treatment of Substance Use Disorders
Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug
More informationAddiction Psychiatry Fellowship Rotation Goals & Objectives
Addiction Psychiatry Fellowship Rotation Goals & Objectives Table of Contents University Neuropsychiatric Institute (UNI) Training Site 2 Inpatient addiction psychiatry rotation.....2 Outpatient addiction
More informationNaltrexone and Alcoholism Treatment Test
Naltrexone and Alcoholism Treatment Test Following your reading of the course material found in TIP No. 28. Please read the following statements and indicate the correct answer on the answer sheet. A score
More informationHeroin Addiction.. Reaching Out!
Miss Seychelles another world 2016 Contestant Number 6 Rita-Maria Durup CONTESTANT PROJECT PROPOSAL Heroin Addiction.. Reaching Out! TABLE OF CONTENT Introduction Page 4 and 5 Objectives Page 6 Expected
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationMethamphetamine. Like heroin, meth is a drug that is illegal in some areas of the world. Meth is a highly addictive drug.
Methamphetamine Introduction Methamphetamine is a very addictive stimulant drug. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she
More informationHow To Understand The Cost Of Jangalak Drug Addicts Hospital
2013 Islamic Republic of Afghanistan Ministry of Public Health General Directorate Policy, Planning and International Relations Health Economics and Financing Directorate Cost Analysis of Jangalak Drug
More informationTENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
More information8/1/2014. Who We Are. BHG s Medical Mission. BHG Company Overview
Who We Are BHG s Medical Mission BHG Company Overview Behavioral Health Group (BHG) is a leading provider of opioid addiction treatment services. Our treatment centers provide pharmacotherapeutic maintenance
More informationMETHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES
METHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES Halina MATSUMOTO, El bieta WO NY, Anna DZIKLIÑSKA, Ma³gorzata ABRAMOWSKA Laboratory of Psychopharmacology, 1st Department of Psychiatry,
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationBehavioral Health Barometer. United States, 2013
Behavioral Health Barometer United States, 2013 Acknowledgments This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by RTI International under contract No.
More informationAppendix D. Behavioral Health Partnership. Adolescent/Adult Substance Abuse Guidelines
Appendix D Behavioral Health Partnership Adolescent/Adult Substance Abuse Guidelines Handbook for Providers 92 ASAM CRITERIA The CT BHP utilizes the ASAM PPC-2R criteria for rendering decisions regarding
More informationDeath in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
More informationOpioid Treatment Services, Office-Based Opioid Treatment
Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,
More informationHulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013
Hulpverleningsmodellen bij opiaatverslaving Frieda Matthys 6 juni 2013 Prevalence The average prevalence of problem opioid use among adults (15 64) is estimated at 0.41%, the equivalent of 1.4 million
More informationDartmouth Medical School Curricular Content in Addiction Medicine for Medical Students (DCAMMS) Keyed to LCME Core Competency Domains ***Draft***
Dartmouth Medical School Curricular Content in Addiction Medicine for Medical Students (DCAMMS) Keyed to LCME Core Competency Domains ***Draft*** This content, sorted by LCME competencies is intended to
More informationAmerican Society of Addiction Medicine
American Society of Addiction Medicine Public Policy Statement on Treatment for Alcohol and Other Drug Addiction 1 I. General Definitions of Addiction Treatment Addiction Treatment is the use of any planned,
More informationCore Competencies for Addiction Medicine, Version 2
Core Competencies for Addiction Medicine, Version 2 Core Competencies, Version 2, was approved by the Directors of the American Board of Addiction Medicine (ABAM) Foundation March 6, 2012 Core Competencies
More informationCancer Treatment Benefit
Cancer Treatment Benefit In Hong Kong, more than 27,000 men and women are newly-diagnosed with cancer each year 1, which means on average one new case is recorded every 20 minutes. Currently 1 in 4 men
More informationJennifer Sharpe Potter, PhD, MPH Associate Professor Division of Alcohol and Drug Addiction Department of Psychiatry
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) Jennifer
More informationRichard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010
Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010 Reference Group to the United Nations on HIV and Injecting Drug Use 2010 Mathers:
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationAcute Pain Management in the Opioid Dependent Patient. Maripat Welz-Bosna MSN, CRNP-BC
Acute Pain Management in the Opioid Dependent Patient Maripat Welz-Bosna MSN, CRNP-BC Relieving Pain in America (IOM) More then 116 Million Americans have pain the persists for weeks to years $560-635
More informationPain Management Regulations Affect More Than Pain Management Specialists January 2012. Of counsel to
Pain Management Regulations Affect More Than Pain Management Specialists January 2012 LINDA A. KEEN MSN, JD, LHCRM LAW OFFICE OF LINDA A. KEEN P.A. TALLAHASSEE, FL Of counsel to Pain Management Regulations
More informationTHE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation 2011. The Issues 5/18/2011. RCGP Conference May 2011
RCGP Conference May 2011 Community Based Medically Assisted Alcohol Withdrawal THE BASICS An option for consideration World Health Organisation 2011 Alcohol is the world s third largest risk factor for
More informationCHEMICAL DEPENDENCE INPATIENT REHABILITATION SERVICES. [Statutory Authority: Mental Hygiene Law Sections 19.07(e), 19.09(b), 19.40, 32.01, 32.
PART 818 CHEMICAL DEPENDENCE INPATIENT REHABILITATION SERVICES [Statutory Authority: Mental Hygiene Law Sections 19.07(e), 19.09(b), 19.40, 32.01, 32.07(a)] Notice: The following regulations are provided
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call
More informationDave Burrows Director
Dave Burrows Director Effects of drug policy on HIV transmission What is the Comprehensive Package of Services for People Who Inject Drugs (PWID) What is an enabling environment for addressing HIV among
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE. Psychosocial interventions in drug misuse
Attachment B NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SPECIAL HEALTH AUTHORITY TENTH WAVE WORK PROGRAMME DRUG MISUSE Psychosocial interventions in drug misuse On 16 th June 2004 the Department of Health
More informationThe prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland
The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland Hannu Alho, Professor Unit on Prevention and Treatment of Addictions, National
More informationMAT Disclosures & Consents 1 of 6. Authorization & Disclosure
MAT Disclosures & Consents 1 of 6 Authorization & Disclosure ***YOUR INSURANCE MAY NOT PAY FOR ROUTINE SCREENING*** *** APPROPRIATE SCREENING DIAGNOSES MUST BE PROVIDED WHEN INDICATED*** Urine Drug Test
More informationHEROIN AND RELATED OPIATES
HEROIN AND RELATED OPIATES DAVID J. NUTT Psychopharmacology Unit, Bristol University Heroin is a derivative of morphine and both belong to a large family of drugs called the opiates, that were originally
More informationAlcohol and Drug Abuse Treatment Centers
Division of State Operated Healthcare Facilities Alcohol and Drug Abuse Treatment Centers Jenny Wood Interim ADATC Team Leader HHS LOC Mental Health Subcommittee February 24, 2014 ADATC Locations R.J.
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationMALAWI YOUTH DATA SHEET 2014
MALAWI YOUTH DATA SHEET 2014 2 of Every 3 People in Malawi Are Under Age 25 Age 80+ 75-79 70-74 65-69 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 Male Female 20-24 POPULATION 700,000 700,000 0 POPULATION
More informationEPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
More informationdrug treatment in england: the road to recovery
The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:
More informationThe Nurse Practitioner in HIV Care. Laura Vicol MN, NP(F) Monica Gregory MScN, NP(F)
The Nurse Practitioner in HIV Care Laura Vicol MN, NP(F) Monica Gregory MScN, NP(F) NURSE PRACTITIONERS First. Who Are we? Nurse Practitioners A New Health Care Provider in the Province of British Columbia
More informationThis brochure explains how alcohol:
When you are HIV positive, you have to work hard to stay healthy. Drinking less alcohol or not drinking at all can help you fight HIV disease and improve your health. Quitting drinking or cutting down
More informationTESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL
TESTING AND MANAGEMENT Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL Disclosure and acknowledgments No conflicts of interest Board Member of Hepatitis
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationThe Utilization Threshold Program
The Utilization Threshold Program In order to contain costs while continuing to provide medically necessary care and services, the Utilization Threshold (UT) program places limits on the number of services
More informationFederal Regulations For Prescribing Scheduled Controlled Substances
Federal Regulations For Prescribing Scheduled Controlled Substances HEIT TEMPLATE.PPT 1 Central Principle of Balance With the Use of Controlled Substances Dual imperative of government Establish a system
More informationBest Practices in Opioid Dependence Treatment
Best Practices in Opioid Dependence Treatment Anthony L. Jordan Health Center Linda Clark, MD, MS Medical Director Alana Ramos, BS Suboxone Clinic Manager Case Studies Nicole White female 27 years of age
More informationModule 4: Formulating M&E Questions and Indicators
Module 4: Formulating M&E Questions and Indicators Four Steps to Developing an Establish the M&E planning team and: M&E Plan 1. Align projects and activities with program goals. 2. Identify information
More informationThe Burden of Pain Among Adults in the United States
P F I Z E R F A C T S The Burden of Pain Among Adults in the United States Findings from the National Health and Nutrition Examination Survey, the National Health Care Surveys, and the National Health
More informationBACKGROUND. ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes
BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective
More informationDrugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP
Drugs and Alcohol in Primary Care Steve Brinksman Clinical Lead SMMGP Habit is habit, and not to be flung out of the window by any man, but coaxed down-stairs one step at a time. Samuel Langhorne Clemens
More informationOPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines
OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines Guideline Evaluation and Treatment Planning Discharge Planning Admission Criteria Continued Stay Criteria Discharge
More informationAmerican Society of Addiction Medicine
American Society of Addiction Medicine Public Policy Statement on Office-based Opioid Agonist Treatment (OBOT) BACKGROUND Methadone maintenance treatment of opioid addiction was developed in 1965 and implemented
More informationMartha Brewer, MS, LPC,LADC. Substance Abuse and Treatment
Martha Brewer, MS, LPC,LADC Substance Abuse and Treatment What is a substance use disorder? Long-term and chronic illness Can affect anyone: rich or poor, male or female, employed or unemployed, young
More informationLoved ones or co-workers may notice a number of signs of heroin use, which are visible during and after heroin consumption:
Introduction Heroin is a highly addictive, illegal drug. It is used by millions of addicts around the world who are unable to overcome the urge to continue taking this drug every day of their lives knowing
More informationThe NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.
New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationAlcoholism and Substance Abuse
State of Illinois Department of Human Services Division of Alcoholism and Substance Abuse OVERVIEW The Illinois Department of Human Services, Division of Alcoholism and Substance Abuse (IDHS/DASA) is the
More informationDRAFT Metropolitan Detention Center (MDC) DWI Addiction Treatment Programs (ATP) Outcome Study Final Report UPDATED
DRAFT Metropolitan Detention Center (MDC) DWI Addiction Treatment Programs (ATP) Outcome Study Final Report UPDATED Prepared for: The DWI Addiction Treatment Programs (ATP) Metropolitan Detention Center
More informationMINISTERIO DE SALUD PUBLICA DIRECCION PROVINCIAL DE SALUD DEL GUAYAS HOSPITAL DE INFECTOLOGIA DR. JOSE DANIEL RODRIGUEZ MARIDUEÑA Guayaquil - Ecuador
EVALUATION OF THE EFFECTIVENESS OF THE PRODUCT BABUNA IN THE TREATMENT OF INSOMNIA, IN PATIENTS OF THE MALE WING OF THE ECUADORIAN HEALTH MINISTRY S HOSPITAL OF INFECTIOUS DISEASE PILLASAGUA Diana, ANDINO
More informationMEWA HIV and Key Population programming
MEWA HIV and Key Population programming Working With People Who Use Drugs Presented by: ABDALLA BADHRUS Program Manager Health And Harm Reduction Services. Muslim Education And Welfare Association Held
More informationScientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances
page 1/5 Scientific Facts on Psychoactive Drugs Tobacco, Alcohol, and Illicit Substances Source document: WHO (2004) Summary & Details: GreenFacts Context - Psychoactive drugs such as tobacco, alcohol,
More informationOverview of the national laws on electronic health records in the EU Member States National Report for Lithuania
Overview of the national laws on electronic health records in the EU Member States and their interaction with the provision of cross-border ehealth services Contract 2013 63 02 Overview of the national
More informationTHE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES
THE OFFICE OF SUBSTANCE ABUSE SERVICES REQUIREMENTS FOR THE PROVISION OF RESIDENTIAL DETOXIFICATION SERVICES BY PROVIDERS FUNDED WITH DBHDS RESOURCES PURPOSE: The goal of this document is to describe the
More informationTestimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of Opioid
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY. Agenda item 12.3 24 May 2014. Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY WHA67.6 Agenda item 12.3 24 May 2014 Hepatitis The Sixty-seventh World Health Assembly, Having considered the report on hepatitis; 1 Reaffirming resolution WHA63.18,
More informationThe Vermont Legislative Research Shop. Methadone
The Vermont Legislative Research Shop Methadone Heroin use statistics in Vermont Heroin treatment admissions in Vermont have risen from around 200 patients in 1994 to 833 patients in 2002 (see Figure 1).
More information5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome
5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is
More information